stockrow
Saturday 7 November 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +12.8%
- Free cash flow
- −94.5%
Quarter to September 2026, against a year earlier
17.63
1.57
+9.78%
Follow JANX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
32.75 | 40.28 | 61.46 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(43.29) | 77.44 | (70.60) | — | |
P/B ratio |
1.20 | 1.04 | 0.93 | — | |
Price to Tangible BV |
1.20 | 1.04 | 0.93 | — | |
EV/Sales |
4.34 | (0.17) | (6.02) | — | |
EV/EBITDA |
0.00 | 0.03 | 0.50 | — | |
EV/Operating CF |
(2.70) | 0.10 | 1.10 | — | |
EV/FCF |
(2.67) | 0.10 | 1.09 | — | |
Quick Ratio |
17.44 | 16.14 | 16.83 | 38.67 | |
Current Ratio |
17.69 | 16.35 | 17.01 | 39.04 | |
Net Debt/EBITDA |
27.71 | 28.46 | 26.30 | 21.26 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.02 | 0.01 | 0.00 | |
Operating CF/Net income |
1.17 | (0.57) | 0.51 | 0.89 | |
Capex/Depreciation |
0.00 | 0.08 | 0.13 | 0.03 | |
Research and Development Expense of Revenue |
329.05% | 301.88% | 718.27% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
107.46% | 106.78% | 298.23% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
91.88% | 88.26% | 248.30% | 0.00% | |
Graham Net Nets |
0.81 | 0.93 | 1.05 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(9.20%) | (10.68%) | (13.24%) | — | |
Free Cash Flow Yield |
(4.97%) | (4.34%) | (9.01%) | — | |
Revenue per Share |
0.15 | 0.16 | 0.06 | 0.00 | |
Operating CF per Share |
(0.40) | 0.20 | (0.20) | (0.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | 0.20 | (0.20) | (0.46) | |
Cash per Share |
14.99 | 15.43 | 15.26 | 15.60 | |
Shareholders Equity per Share |
14.45 | 14.74 | 15.02 | 15.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.45 | 14.74 | 15.02 | 15.44 | |
Free Cash Flow |
(25.18) | 12.28 | (12.61) | (28.65) | |
Working Capital |
905.14 | 923.19 | 943.13 | 950.89 | |
Capital Expenditures |
0.00 | (0.20) | (0.27) | (0.11) | |
Net Current Asset Value |
887.34 | 903.67 | 915.36 | 931.14 | |
EV/EBIT |
0.00 | 0.03 | 0.54 | — | |
Capex to Sales |
0.00 | 0.02 | 0.07 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.47 | 0.92 | 18.25 | — | |
Average Payables |
3.85 | 3.25 | 2.86 | 4.50 | |
Average Assets |
1,004.21 | 1,019.93 | 1,039.50 | 1,031.54 | |
Average Common Equity |
944.08 | 959.25 | 977.00 | 989.80 |
Columns are period end dates · fundamentals updated 5 Nov 2026